Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naive Patients with Chronic Spontaneous Urticaria.

ABSTRACT:

Introduction

Chronic spontaneous urticaria (CSU) is characterized by itchy hives with or without angioedema recurring for > 6 weeks. Many patients experience a substantial disease burden despite H1-antihistamine treatment, including impaired health-related quality of life (HRQoL). In the current analysis, we evaluated the efficacy of dupilumab in improving HRQoL in omalizumab-naïve patients with CSU.

Methods

LIBERTY-CSU CUPID Study A was a double-blind, phase 3 trial that evaluated the efficacy and safety of dupilumab in patients aged ≥ 6 years with CSU who remained symptomatic despite H1-antihistamine treatment. Patients were randomized to receive dupilumab 300 mg every 2 weeks (q2w; n = 70) or placebo q2w (n = 68). The current analysis evaluated the change from baseline to

SUBMITTER: Gimenez-Arnau AM 

PROVIDER: S-EPMC12873032 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature